title: Increased phospholipase A2 activity in schizophrenia with absent response to niacin.
abstract: An absent response to the niacin skin test has been reported to occur in about 80% of schizophrenic patients, as compared to 20% of healthy individuals. Niacin provokes redness in skin caused by a capillary vasodilatation mediated by prostaglandins. The metabolism of prostaglandins is regulated by the enzyme phospholipase A2 (PLA2). Several studies have reported increased PLA2 activity in schizophrenia. In this study we investigated the relationship between niacin response and PLA2 activity in 38 drug-free schizophrenic patients and in 28 healthy controls. Twenty-two of these patients were reevaluated after 8 weeks under treatment with new generation antipsychotic drugs. Niacin response was absent in 23% of the schizophrenic patients and in 14% in controls (n.s.). PLA2 activity was higher in schizophrenics than in controls (344+/-115 vs. 290+/-71 pmol/ml/min; p=0.03). Patients with absent response to niacin had the highest PLA2 activity as compared to those with positive response (426+/-155 vs. 319+/-111; p=0.02). After 8 weeks on antipsychotic treatment, PLA2 activity was reduced (355+/-115 before, 267+/-39 after, p=0.001) and 4 out of 13 patients with absent response to niacin converted to positive. The reduction of PLA2 activity in these patients was higher than in patients who remained with absent response (36% vs. 23%). Our data support the findings that absent response to niacin is more frequent in schizophrenic than in healthy individuals although the magnitude of the difference was smaller than that reported in the literature. The relationship between absent response to niacin in schizophrenia and increased PLA2 activity suggests further that the skin test may be useful to easily identify a subgroup of patients with a disordered phospholipid metabolism.
authors.affiliation: Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Rua Dr. Ovídio Pires de Campos s/n, P.O. Box 3671, Brazil.
authors.forename: Hildeberto
authors.initials: H
authors.lastname: Tavares
authors.forename: Juliana
authors.initials: J
authors.lastname: Yacubian
authors.forename: Leda L
authors.initials: LL
authors.lastname: Talib
authors.forename: Nádia R
authors.initials: NR
authors.lastname: Barbosa
authors.forename: Wagner F
authors.initials: WF
authors.lastname: Gattaz
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005470:Fluorometry; D006801:Humans; D008297:Male; D009525:Niacin / Q000008:administration & dosage / Q000494:pharmacology*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D010743:Phospholipids / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D012867:Skin / Q000187:drug effects; D012882:Skin Tests
chemical_list: D014150:Antipsychotic Agents; D010743:Phospholipids; D011453:Prostaglandins; D009525:Niacin; D010741:Phospholipases A; D054467:Phospholipases A2